Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases by Farmer, Luc J, Ledeboer, Mark W, Hoock, Thomas, Arnost, Michael J, Bethiel, Randy S, Bennani, Youssef L, Black, James J, Brummel, Christopher L, Chakilam, Ananthsrinivas, Dorsch, Warren A, Fan, Bin, Cochran, John E, Halas, Summer, Harrington, Edmund M, Hogan, James K, Howe, David, Huang, Hui, Jacobs, Dylan H, Laitinen, Leena M, Liao, Shengkai, Mahajan, Sudipta, Marone, Valerie, Martinez-Botella, Gabriel, McCarthy, Pamela, Messersmith, David, Namchuk, Mark, Oh, Luke, Penney, Marina S, Pierce, Albert C, Raybuck, Scott A, Rugg, Arthur, Salituro, Francesco G, Saxena, Kumkum, Shannon, Dean, Shlyakter, Dina, Swenson, Lora, Tian, Shi-Kai, Town, Christopher, Wang, Jian, Wang, Tiansheng, Wannamaker, M. Woods, Winquist, Raymond J, Zuccola, Harmon J

Get full text

Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin by Zeremski, Marija, Dimova, Rositsa B., Benjamin, Samantha, Penney, Marina S., Botfield, Martyn C., Talal, Andrew H.

Get full text

A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer by Tang, Stephen, Sethunath, Vidyalakshmi, Metaferia, Nebiyou Y., Nogueira, Marina F., Gallant, Daniel S., Garner, Emma R., Lairson, Lauren A., Penney, Christopher M., Li, Jiao, Gelbard, Maya K., Alaiwi, Sarah Abou, Seo, Ji-Heui, Hwang, Justin H., Strathdee, Craig A., Baca, Sylvan C., AbuHammad, Shatha, Zhang, Xiaoyang, Doench, John G., Hahn, William C., Takeda, David Y., Freedman, Matthew L., Choi, Peter S., Viswanathan, Srinivas R.

Get full text

Airway Epithelial STAT3 Is Required for Allergic Inflammation in a Murine Model of Asthma by Simeone-Penney, Marina C, Severgnini, Mariano, Tu, Powen, Homer, Robert J, Mariani, Thomas J, Cohn, Lauren, Simon, Amy R

Get full text

PDGF-induced human airway smooth muscle cell proliferation requires STAT3 and the small GTPase Rac1 by Simeone-Penney, Marina C, Severgnini, Mariano, Rozo, Lilliana, Takahashi, Satoe, Cochran, Brent H, Simon, Amy R

Get full text

Abstract 3711: Pre-clinical combinations of ATR and PARP inhibitors: Defining target patient populations and dose schedule by Pollard, John, Reaper, Phil, Peek, Adele, Hughes, Stuart, Djeha, Hakim, Cummings, Steven, Larbi, Karen, Penney, Marina, Sullivan, Jim, Takemoto, Darin, DeFranco, Chris

Get full text

Abstract 3716: Potent radiation enhancement with VX-984, a selective DNA-PKcs inhibitor for the treatment of NSCLC by Boucher, Diane, Hoover, Russell, Wang, Yuxin, Gu, Yong, Newsome, David, Ford, Pamella, Moody, Cameron, Damagnez, Veronique, Arimoto, Reiko, Hillier, Shawn, Wood, Mark, Markland, William, Eustace, Brenda, Cottrell, Kevin, Penney, Marina, Furey, Brinley, Tanner, Kirk, Maxwell, John, Charifson, Paul

Get full text

Abstract CT012: Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792) by Shapiro, Geoffrey, Wesolowski, Robert, Middleton, Mark, Devoe, Craig, Constantinidou, Anastasia, Papadatos-Pastos, Dionysis, Fricano, Marjorie, Zhang, Yanqiong, Karan, Sharon, Pollard, John, Penney, Marina, Asmal, Mohammed, Renshaw, F. Gary, Fields, Scott Z., Yap, Timothy A.

Get full text

Abstract 3717: Defining optimal dose schedules for ATR inhibitors in combination with DNA damaging drugs: Informing clinical studies of VX-970, the first-in-class ATR inhibitor by Pollard, John, Reaper, Phil, Peek, Adele, Hughes, Stuart, Gladwell, Scott, Jones, Julie, Chiu, Peter, Wood, Mark, Tolman, Crystal, Johnson, Mac, Littlewood, Peter, Penney, Marina, McDermott, Katherine, Hare, Brian, Fields, Scott Z., Asmal, Mohammed, O’Carrigan, Brent, Yap, Timothy A.

Get full text

Abstract 1644: VX-970, the first-in-class inhibitor of the DNA damage repair enzyme ATR by Pollard, John, Reaper, Philip, Jones, Julie, Barnes, Christopher, Gladwell, Scott, Hughes, Stuart, Peak, Adele, Djeha, Hakim, Hall, Amy, Newsome, David, Wang, Yuxin, Boucher, Diane, Eustace, Brenda, Gu, Yong, Hare, Brian, Johnson, Mac, Milton, Sean, Murphy, Cheryl, Takemoto, Darin, Tolman, Crystal, Wood, Mark, Furey, Brinley, Penney, Marina, Li, Howard, Defranco, Christopher, Asmal, Mohammed, Fields, Scott

Get full text

Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) i... by Yap, Timothy A., Luken, Maria J. de Miguel, O'Carrigan, Brent, Roda, Desam, Papadatos-Pastos, Dionysis, Lorente, David, Tunariu, Nina, Lopez, Raquel Perez, Gayle, Sasha, Riisnaes, Ruth, Figueiredo, Ines, Miranda, Susana, Carreira, Suzanne, Yang, Fang, Karan, Sharon, Penney, Marina, Pollard, John, Molife, L. Rhoda, Banerji, Udai, Asmal, Mohammed, Fields, Scott Z., Bono, Johann S. de

Get full text

Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study by Li, Jian-Liang, Hayden, Michael R, Warby, Simon C, Durr, Alexandra, Morrison, Patrick J, Nance, Martha, Ross, Christopher A, Margolis, Russell L, Rosenblatt, Adam, Squitieri, Ferdinando, Frati, Luigi, Gómez-Tortosa, Estrella, García, Carmen Ayuso, Suchowersky, Oksana, Klimek, Mary Lou, Trent, Ronald J A, McCusker, Elizabeth, Novelletto, Andrea, Frontali, Marina, Paulsen, Jane S, Jones, Randi, Ashizawa, Tetsuo, Lazzarini, Alice, Wheeler, Vanessa C, Prakash, Ranjana, Xu, Gang, Djoussé, Luc, Mysore, Jayalakshmi Srinidhi, Gillis, Tammy, Hakky, Michael, Cupples, L Adrienne, Saint-Hilaire, Marie H, Cha, Jang-Ho J, Hersch, Steven M, Penney, John B, Harrison, Madaline B, Perlman, Susan L, Zanko, Andrea, Abramson, Ruth K, Lechich, Anthony J, Duckett, Ayana, Marder, Karen, Conneally, P Michael, Gusella, James F, MacDonald, Marcy E, Myers, Richard H

Get full text